Copyright
©The Author(s) 2015.
World J Gastroenterol. Jan 7, 2015; 21(1): 229-232
Published online Jan 7, 2015. doi: 10.3748/wjg.v21.i1.229
Published online Jan 7, 2015. doi: 10.3748/wjg.v21.i1.229
Table 2 Proportions with prior medication exposures divided by group n (%)
| Class | Medication | Hair loss n = 50 | No hair loss n = 100 | P value |
| Aminosalicylate | ||||
| Mesalamine | 27 (54) | 73 (73) | 0.03 | |
| Immunomodulators | ||||
| 6-mercaptopurine/Azathioprine | 8 (16) | 16 (16) | 1.0 | |
| Methotrexate | 5 (10) | 11 (11) | 1.0 | |
| Anti-TNF’s | ||||
| Anti-TNF | 8 (16) | 56 (56) | 0.001 | |
| Infliximab | 3 (6) | 25 (25) | 0.01 | |
| Adalimumab | 4 (8) | 17 (17) | 0.21 | |
| Certolizumab | 2 (4) | 14 (14) | 0.09 | |
| Steroids | ||||
| Prednisone | 24 (48) | 48 (48) | 1.0 | |
| Budesonide | 5 (10) | 13 (13) | 0.81 |
- Citation: Shah R, Abraham B, Hou J, Sellin J. Frequency and associated factors of hair loss among patients with inflammatory bowel disease. World J Gastroenterol 2015; 21(1): 229-232
- URL: https://www.wjgnet.com/1007-9327/full/v21/i1/229.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i1.229